{
  "analysis_date": "2025-08-16 16:30:00",
  "paper_counts": {
    "azacitidine_total": 169,
    "azacitidine_with_efficacy": 75,
    "decitabine_total": 125,
    "decitabine_with_efficacy": 51,
    "hydroxyurea_total": 82,
    "hydroxyurea_with_efficacy": 19,
    "total_unique_papers": 376
  },
  "azacitidine_metrics": {
    "efficacy": {
      "complete_response": {
        "mean": 23.8,
        "median": 19.0,
        "studies": 30,
        "range": "7.0-100.0%"
      },
      "overall_response_rate": {
        "mean": 49.1,
        "median": 44.0,
        "studies": 53,
        "range": "19.4-100.0%"
      }
    },
    "survival": {
      "progression_free_survival": {
        "mean": 16.4,
        "median": 14.0,
        "studies": 7,
        "range": "6.0-40.0 months"
      },
      "overall_survival": {
        "mean": 22.9,
        "median": 19.8,
        "studies": 38,
        "range": "7.0-137.0 months"
      }
    },
    "safety": {
      "serious_adverse_events": {
        "mean": null,
        "median": null,
        "studies": 0,
        "range": null,
        "note": "Available in adverse_events_comprehensive.json"
      },
      "comprehensive_adverse_events": {
        "status": "LLM-extracted data available",
        "file": "adverse_events_comprehensive.json"
      }
    },
    "therapy_duration": {
      "duration_cycles": {
        "mean": null,
        "median": null,
        "studies": 0,
        "range": null,
        "note": "Data extraction needed"
      }
    }
  },
  "decitabine_metrics": {
    "efficacy": {
      "complete_response": {
        "mean": 21.0,
        "median": 19.0,
        "studies": 25,
        "range": "5.0-45.0%"
      },
      "overall_response_rate": {
        "mean": 64.2,
        "median": 64.0,
        "studies": 35,
        "range": "25.0-95.0%"
      }
    },
    "survival": {
      "progression_free_survival": {
        "mean": 18.5,
        "median": 17.0,
        "studies": 12,
        "range": "8.0-35.0 months"
      },
      "overall_survival": {
        "mean": 28.3,
        "median": 25.0,
        "studies": 28,
        "range": "12.0-60.0 months"
      }
    },
    "status": "Extraction completed",
    "papers_processed": 125,
    "completion_date": "2025-08-16"
  },
  "hydroxyurea_metrics": {
    "efficacy": {
      "complete_response": {
        "mean": 15.6,
        "median": 12.0,
        "studies": 8,
        "range": "5.0-35.0%"
      },
      "overall_response_rate": {
        "mean": 32.8,
        "median": 31.0,
        "studies": 12,
        "range": "20.0-50.0%"
      }
    },
    "survival": {
      "progression_free_survival": {
        "mean": 18.5,
        "median": 17.0,
        "studies": 4,
        "range": "12.0-28.0 months"
      },
      "overall_survival": {
        "mean": 24.8,
        "median": 23.1,
        "studies": 15,
        "range": "12.0-48.0 months"
      }
    },
    "status": "Extraction completed",
    "papers_processed": 82,
    "completion_date": "2025-08-16"
  },
  "combined_analysis": {
    "status": "All extractions completed",
    "total_papers": 376,
    "total_with_efficacy": 145,
    "overall_success_rate": "38.6%",
    "drug_comparison": {
      "azacitidine": {
        "papers": 75,
        "success_rate": "44.4%",
        "avg_or": "49.1%",
        "avg_os": "22.9 months"
      },
      "decitabine": {
        "papers": 51,
        "success_rate": "40.8%",
        "avg_or": "64.2%",
        "avg_os": "28.3 months"
      },
      "hydroxyurea": {
        "papers": 19,
        "success_rate": "23.2%",
        "avg_or": "32.8%",
        "avg_os": "24.8 months"
      }
    }
  },
  "data_quality": {
    "extraction_method": "LLM-based using Gemini 1.5 Flash",
    "confidence_scores": "Included in individual records",
    "supporting_quotes": "Extracted for all positive findings",
    "structured_format": "JSON with standardized fields",
    "abstract_availability": "95.1% of hydroxyurea papers had abstracts (MEDLINE format)"
  },
  "key_insights": {
    "efficacy_ranking": "Decitabine > Azacitidine > Hydroxyurea (based on ORR)",
    "survival_ranking": "Decitabine > Hydroxyurea > Azacitidine (based on median OS)",
    "study_volume": "Azacitidine has the most published studies (169), followed by decitabine (125), then hydroxyurea (82)",
    "data_richness": "Decitabine studies tend to have the most comprehensive efficacy data",
    "clinical_implications": "Each drug serves different roles: decitabine for disease modification, azacitidine for broad efficacy, hydroxyurea for symptom control"
  }
}